{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-013975","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.708995+00:00","generated_at":"2026-05-17T06:17:38.592825+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kairos Pharma reports positive Phase 2 interim efficacy for ENV105 in mCRPC; median PFS >13 months","bullets":["Median PFS >13 months in 8 evaluable patients with mCRPC who failed prior hormone therapy.","5 of 8 patients continuing without progression; 7 of 9 showed PSA decrease from baseline.","Trial powered for 45% PFS improvement; actual PFS far exceeded CARD trial benchmark of 3.7-6.7 months.","No Grade 3/4 toxicities observed; ENV105 well tolerated with standard supportive care.","Phase 2 trial enrolling at Cedars-Sinai, City of Hope, Huntsman Cancer Center; KOL event held Sept 18."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-013975","json":"https://secwatch.observer/filing/0001493152-25-013975.json","markdown":"https://secwatch.observer/filing/0001493152-25-013975.md","text":"https://secwatch.observer/filing/0001493152-25-013975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225013975/0001493152-25-013975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225013975/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:17:38.592825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}